VRXAW
Veraxa Biotech AG WarrantsKey Statistics
About Veraxa Biotech AG Warrants
Veraxa Biotech AG Warrants (VRXAW) is an innovative biotechnology company dedicated to developing cutting-edge therapies that address unmet medical needs across diverse therapeutic areas. With a strong focus on advancing novel drug candidates, the firm boasts a robust pipeline supported by rigorous research and development practices. Leveraging proprietary technologies and fostering collaborative partnerships within the biotech ecosystem, Veraxa Biotech is strategically positioned for growth, making it an attractive investment opportunity for institutional investors seeking exposure to the evolving healthcare sector.
Fundamentals
| Revenue (TTM) | 23,430 |
| Gross Profit (TTM) | 15,460 |
| EBITDA | $-64.24M |
| Operating Margin | -282663.00% |
| Return on Equity | -871.00% |
| Return on Assets | -50.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-1.30 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $3.84M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VRXAW and any ticker you trade — then tracks every position and per-strategy win rate.